USPTO Examiner TIEN LUCY MINYU - Art Unit 1612

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18440894N-(PYRIMIDIN-2-YLCARBAMOTHIOYL) BENZAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)February 2024June 2024Allow400NoNo
18506961TADALAFIL ORAL TRANSMUCOSAL FILMNovember 2023March 2024Allow410YesNo
18383326N-(PYRIMIDIN-2-YLCARBAMOTHIOYL) BENZAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)October 2023November 2024Abandon1321NoNo
18374342Broad-Spectrum Antimicrobial, Biocompatible and Preservative-Free Functionalized Fullerenes Ophthalmic Solution with Reactive Oxygen Species Scavenging and Advanced Targeting, Penetration, and Hydration.September 2023April 2024Allow710YesNo
18477161EPINEPHRINE FORMULATIONSSeptember 2023December 2024Allow1530NoNo
18470256EPINEPHRINE FORMULATIONSSeptember 2023April 2025Abandon1820NoNo
18070570Method of Improving the Appearance of SkinNovember 2022September 2024Allow2220NoNo
17988031ARCTIGENIN LIQUID NANO-PREPARATION AND PREPARATION METHOD THEREOFNovember 2022June 2024Allow1920NoNo
17985933OIL-IN-WATER TYPE COSMETIC COMPOSITION WITH VISIBLE OIL PARTICLESNovember 2022May 2024Abandon1820NoNo
17969309Fiber-Reinforced Bio-Material Composition and Methods of UseOctober 2022March 2025Allow2920NoNo
18046553ORODISPERSIBLE FORMULATIONSOctober 2022November 2024Allow2550YesNo
17936440LEAVE-ON HAIR TREATMENT COMPOSITIONSSeptember 2022March 2024Allow1820YesNo
17935651CLEANSING COMPOSITIONS COMPLETELY BASED ON BIO-RENEWABLE SOURCESSeptember 2022August 2023Allow1010NoNo
17949576ORAL SUPPLEMENT FOR PREVENTING COLIC IN HORSESSeptember 2022March 2024Allow1720NoNo
17900091NOVEL ENVIRONMENT-FRIENDLY HERBICIDEAugust 2022November 2024Abandon2611NoNo
17898685DISSOLVABLE SOLID STRUCTURE COMPRISING FIRST AND SECOND POLYMERIC STRUCTURANTSAugust 2022May 2025Allow3350YesNo
17815268HAIR COLORING WITH COCONUT OILJuly 2022May 2025Allow3330YesNo
17852555Original Healing GelJune 2022March 2024Abandon2120NoNo
17826035CLAY MASK FOR TREATING SKINMay 2022December 2023Abandon1910NoNo
17744257COSMETIC COMPOSITION AND METHODMay 2022April 2025Abandon3531YesNo
17738697Shampoo Compositions Containing a Sulfate-Free Surfactant System and Sclerotium Gum ThickenerMay 2022August 2024Allow2720YesYes
17730382HAIR COMPOSITIONSApril 2022December 2023Allow2010NoNo
17686880PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOFMarch 2022June 2025Allow3911NoNo
17685487MOLDABLE COMPOSITION FOR SOLID WASHING AGENT AND METHOD FOR MOLDING THE SAMEMarch 2022August 2024Allow3020YesNo
17685574TREATMENT COMPOSITION FOR NASAL AND ORAL DRYNESS, NOSEBLEEDS, AND ALLERGY SYMPTOMSMarch 2022March 2024Allow2520YesNo
17685090EPINEPHRINE FORMULATIONSMarch 2022June 2025Allow4010NoNo
17652518BLEACHING COMPOSITION FOR KERATIN FIBERSFebruary 2022December 2024Allow3430YesNo
17676628PETROLATUM ALTERNATIVE FROM RENEWABLE SOURCESFebruary 2022November 2023Abandon2110NoNo
17561872Alcohol Soluble Biodegradable CompositionsDecember 2021May 2024Allow2911NoNo
17560594PEGYLATED LIPOSOMES AND METHODS OF USEDecember 2021January 2025Allow3710NoNo
17553172PORTION UNIT WITH COSMETIC AGENT FOR LIGHTENING KERATINOUS FIBERS, ESPECIALLY HUMAN HAIRDecember 2021December 2024Abandon3610NoNo
17553146PORTION UNIT WITH COSMETIC PRODUCT FOR OXIDATIVE COLOR CHANGE OF KERATINOUS FIBERSDecember 2021September 2024Abandon3320NoNo
17537856AQUEOUS COMPOSITION OF EPYRIFENACIL, FLUMIOXAZIN AND PYROXASULFONENovember 2021March 2025Allow4040NoNo
17523105SYSTEM AND METHOD OF TREATING INFLAMMATORY LUNG DISEASESNovember 2021December 2023Abandon2511NoNo
17517763FAST-DISINTEGRATING SOLID HERBICIDE COMPOSITION AND THE USE THEREOFNovember 2021February 2024Abandon2711NoNo
17495104STABLE FORMULATIONS OF LIPIDS AND LIPOSOMESOctober 2021September 2024Allow3610NoNo
17445089LIPOSOMAL FORMULATION FOR JOINT LUBRICATIONAugust 2021September 2024Allow3710NoNo
17372952SMALL MOLECULE PATHOGEN DISPERSAL AGENTJuly 2021December 2024Abandon4240NoNo
17312927SOLID FORMULATION OF HERBICIDAL COMPOSITION AND PREPARING METHOD THEREOFJune 2021October 2024Abandon4010NoNo
17299636NANOEMULSION HYDROPHOBIC SUBSTANCESJune 2021July 2024Abandon3711NoNo
17306244MICRONIZED LIPIDSMay 2021September 2024Allow4131YesNo
17306261MICRONIZED LIPIDSMay 2021September 2024Allow4131YesNo
17284984A CHEWABLE TABLET AND METHOD OF PREPARING THE SAMEApril 2021September 2024Allow4230NoNo
17283375LIP COSMETIC COMPOSITION AND USE THEREOFApril 2021September 2023Abandon2910NoNo
17283216SILICON FREE HAIR CONDITIONING COMPOSITIONApril 2021June 2025Allow5070NoNo
17282085IMPROVED-STRENGTH HARD CAPSULE AND PRODUCTION METHOD FOR SAMEApril 2021March 2025Abandon4731NoNo
17281621ASENAPINE-CONTAINING ADHESIVE PATCHMarch 2021September 2023Allow3020NoNo
17218438HAIR CARE COMPOSITIONSMarch 2021March 2023Allow2410NoNo
17281312CORE-SHELL COMPOSITE AND A PROCESS OF PREPARING THE SAMEMarch 2021July 2024Abandon3901NoNo
17281442SPHERICAL BEADS FOR USE IN PRODUCING PHARMACEUTICALLY ACTIVE PELLETSMarch 2021July 2024Allow4031NoNo
17213350SHEET TYPE MASK GEL COMPOSITION, MASK SHEET COMPRISING THE SAME, AND MANUFACTURING METHOD OF MASK SHEETMarch 2021February 2024Allow3511YesNo
17279768COSMETIC GEL COMPRISING A TRIGLYCERIDE OILMarch 2021May 2024Allow3821YesNo
17279151COMPOSITION AND METHOD FOR SHAPING OR ALTERING THE SHAPE OF HAIR, METHOD FOR MANUFACTURING A COMPOSITION, KIT AND USES OF A COMPOSITIONMarch 2021December 2023Allow3311NoNo
17208025COMPOSITION FOR CONTROLLING AND PREVENTING BACTERIAL WILTMarch 2021May 2024Abandon3820NoYes
17277825LIPOPHILIC TRANSPORT PARTICLES FOR COSMETIC OR PHARMACEUTICAL ACTIVE INGREDIENTSMarch 2021June 2024Allow3931YesYes
17277213HAIR TREATMENT COMPOSITIONMarch 2021August 2023Allow2920YesNo
17275973STABILIZED CYCLOHEXANEDIONE OXIME COMPOSITIONMarch 2021May 2024Allow3821YesNo
17275225METHOD OF CONTROLLING PESTS BY SEED TREATMENT APPLICATION OF A MESOIONIC COMPOUND OR MIXTURE THEREOFMarch 2021November 2024Abandon4531NoNo
17265692IMMUNOREACTANT CARRIERFebruary 2021March 2025Allow5031NoNo
17140502LIPOSOME COMPOSITION AND METHOD FOR PRODUCING THE SAMEJanuary 2021October 2024Allow4540NoNo
16651062COMPOSITIONS AND METHODS FOR IMPROVING NITROGEN UTILIZATION IN A RUMINANTMarch 2020November 2024Allow5550YesNo
16235950SCALE UP SYNTHESIS OF SILICASOME NANOCARRIERSDecember 2018March 2025Allow6081YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner TIEN, LUCY MINYU.

Strategic Value of Filing an Appeal

Total Appeal Filings
3
Allowed After Appeal Filing
1
(33.3%)
Not Allowed After Appeal Filing
2
(66.7%)
Filing Benefit Percentile
47.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner TIEN, LUCY MINYU - Prosecution Strategy Guide

Executive Summary

Examiner TIEN, LUCY MINYU works in Art Unit 1612 and has examined 61 patent applications in our dataset. With an allowance rate of 67.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner TIEN, LUCY MINYU's allowance rate of 67.2% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by TIEN, LUCY MINYU receive 2.23 office actions before reaching final disposition. This places the examiner in the 76% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by TIEN, LUCY MINYU is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +41.3% benefit to allowance rate for applications examined by TIEN, LUCY MINYU. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.8% of applications are subsequently allowed. This success rate is in the 53% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 28.6% of cases where such amendments are filed. This entry rate is in the 32% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 40.0% are granted (fully or in part). This grant rate is in the 38% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.